Distinguished in Ovarian Carcinosarcoma

Dr. Matthew Block

Hematology | Oncology
Rochester, MN 
Distinguished in Ovarian Carcinosarcoma
Rochester, MN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Matthew Block is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Block is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Melanoma, Ovarian Cancer, Endometrial Cancer, and Ovarian Carcinosarcoma.

His clinical research consists of co-authoring 111 peer reviewed articles and participating in 19 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in MN
Hospital Affiliations
Mayo Clinic Health System In Red Wing
Mayo Clinic Hospital Rochester
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
South Country Health Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

MAYO CLINIC
Rochester, MN 55902
Other Locations
MAYO CLINIC
200 1st St Sw, Rochester, MN 55905

Additional Areas of Focus

Dr. Block has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Neoadjuvant Therapy for Patients With High Risk Stage III Melanoma: A Pilot Clinical Trial
Neoadjuvant Therapy for Patients With High Risk Stage III Melanoma: A Pilot Clinical Trial
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Atezolizumab, Cobimetinib, Vemurafenib
Study Phase: Phase 2
MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
Enrollment Status: Terminated
Publish Date: August 26, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Gemcitabine Hydrochloride, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
Phase I Study of Pembrolizumab in Combination With Ibrutinib in the Treatment of Unresectable or Metastatic Melanoma
Phase I Study of Pembrolizumab in Combination With Ibrutinib in the Treatment of Unresectable or Metastatic Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Ibrutinib, Pembrolizumab
Study Phase: Phase 1
A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cabozantinib S-malate, Nivolumab
Study Phase: Phase 2
Phase Ib/II Study of Autologous Dendritic Cell Therapy Delivered Intratumorally After Cryoablation in Combination With Pembrolizumab for Patients With Metastatic or Unresectable Melanoma
Phase Ib/II Study of Autologous Dendritic Cell Therapy Delivered Intratumorally After Cryoablation in Combination With Pembrolizumab for Patients With Metastatic or Unresectable Melanoma
Enrollment Status: Terminated
Publish Date: June 12, 2025
Intervention Type: Procedure, Biological
Study Drugs: Pembrolizumab, Therapeutic Autologous Dendritic Cells
Study Phase: Phase 1/Phase 2
A Pilot Study of the Safety and Immunogenicity of Folate Receptor Alpha Peptide-Loaded Dendritic Cell Vaccination in Patients With Advanced Stage Epithelial Ovarian Cancer
A Pilot Study of the Safety and Immunogenicity of Folate Receptor Alpha Peptide-Loaded Dendritic Cell Vaccination in Patients With Advanced Stage Epithelial Ovarian Cancer
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Biological, Other
Study Drug: Multi-Epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
Study Phase: Early Phase 1
Phase I Trial to Evaluate the Safety and Efficacy of Intratumoral and Intravenous Injection of Vesicular Stomatitis Virus Expressing Human Interferon Beta and Tyrosinase Related Protein 1 (VSV-IFNb-TYRP1) in Patients With Metastatic Ocular Melanoma and Previously Treated Patients With Unresectable Stage III/IV Cutaneous Melanoma
Phase I Trial to Evaluate the Safety and Efficacy of Intratumoral and Intravenous Injection of Vesicular Stomatitis Virus Expressing Human Interferon Beta and Tyrosinase Related Protein 1 (VSV-IFNb-TYRP1) in Patients With Metastatic Ocular Melanoma and Previously Treated Patients With Unresectable Stage III/IV Cutaneous Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: May 18, 2025
Intervention Type: Drug
Study Drug: Recombinant Vesicular Stomatitis Virus-Expressing Interferon-Beta and Tyrosinase Related Protein 1
Study Phase: Phase 1
A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope Folate Receptor Alpha Peptide Vaccine Used in Combination With Cyclophosphamide in Subjects Previously Treated for Breast or Ovarian Cancer
A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope Folate Receptor Alpha Peptide Vaccine Used in Combination With Cyclophosphamide in Subjects Previously Treated for Breast or Ovarian Cancer
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug, Other, Biological
Study Phase: Phase 1
Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)
Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Drug, Other, Biological
Study Drugs: Bevacizumab, Nab-Paclitaxel
Study Phase: Phase 1
A Phase 1 Cross-over Biodistribution Study of [203Pb]VMT01 for Single Photon Emission Computed Tomography (SPECT) Imaging and [68Ga]VMT02 for Positron Emission Tomography (PET) Imaging of Stage IV Metastatic Melanoma
A Phase 1 Cross-over Biodistribution Study of [203Pb]VMT01 for Single Photon Emission Computed Tomography (SPECT) Imaging and [68Ga]VMT02 for Positron Emission Tomography (PET) Imaging of Stage IV Metastatic Melanoma
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug
Study Drugs: [203Pb]VMT01, [68Ga]VMT02
Study Phase: Phase 1
A Randomized Multicenter Phase II Trial to Evaluate the Safety, Efficacy and Immunogenicity of Vaccination With Folate Receptor Alpha Peptides With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer and a Response or Stable Disease to Platinum Therapy
A Randomized Multicenter Phase II Trial to Evaluate the Safety, Efficacy and Immunogenicity of Vaccination With Folate Receptor Alpha Peptides With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer and a Response or Stable Disease to Platinum Therapy
Enrollment Status: Terminated
Publish Date: December 15, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

111 Total Publications

ASO Visual Abstract: Accuracy of PET-CT to Assess the Extent of Nodal Disease in Patients with Clinical Stage III Melanoma Following Neoadjuvant Treatment.
ASO Visual Abstract: Accuracy of PET-CT to Assess the Extent of Nodal Disease in Patients with Clinical Stage III Melanoma Following Neoadjuvant Treatment.
Journal: Annals of surgical oncology
Published: September 16, 2025
Similar Doctors
Distinguished in Ovarian Carcinosarcoma
Dr. Saravut Weroha
Hematology | Oncology
Distinguished in Ovarian Carcinosarcoma
Dr. Saravut Weroha
Hematology | Oncology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
 (0.8 miles away)
507-284-2512
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Saravut Weroha is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Weroha is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Ovarian Cancer, Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, Desmoplastic Small Round Cell Tumor, and Salpingo-Oophorectomy.

Distinguished in Ovarian Carcinosarcoma
Dr. Andrea Wahner
Hematology | Oncology
Distinguished in Ovarian Carcinosarcoma
Dr. Andrea Wahner
Hematology | Oncology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
 (0.8 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances

Andrea Wahner is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Wahner is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Ovarian Cancer, Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, and Desmoplastic Small Round Cell Tumor.

Distinguished in Ovarian Carcinosarcoma
Dr. Aminah Jatoi
Hematology | Oncology
Distinguished in Ovarian Carcinosarcoma
Dr. Aminah Jatoi
Hematology | Oncology
200 1st St Sw, 
Rochester, MN 
 (0.8 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances

Aminah Jatoi is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Jatoi is rated as an Advanced provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Ovarian Cancer, Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, and Endometrial Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Block's expertise for a condition
ConditionClose
View All 47 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile